Deferred Tax Assets, Valuation Allowance of Blueprint Medicines Corp from 31 Dec 2013 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Blueprint Medicines Corp quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2024.
  • Blueprint Medicines Corp Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $798,096,000, a 3% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Blueprint Medicines Corp Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $798,096,000 +$23,330,000 +3% 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q4 2023 $774,766,000 +$149,671,000 +24% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q4 2022 $625,095,000 +$148,915,000 +31% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q4 2021 $476,180,000 +$147,738,000 +45% 31 Dec 2021 10-K 16 Feb 2023 2022 FY
Q4 2020 $328,442,000 -$41,937,000 -11% 31 Dec 2020 10-K 16 Feb 2023 2022 FY
Q4 2019 $370,379,000 +$136,873,000 +59% 31 Dec 2019 10-K 17 Feb 2022 2021 FY
Q4 2018 $233,506,000 +$119,028,000 +104% 31 Dec 2018 10-K 17 Feb 2021 2020 FY
Q4 2017 $114,478,000 +$30,425,000 +36% 31 Dec 2017 10-K 13 Feb 2020 2019 FY
Q4 2016 $84,053,000 +$31,129,000 +59% 31 Dec 2016 10-K 26 Feb 2019 2018 FY
Q4 2015 $52,924,000 +$19,849,000 +60% 31 Dec 2015 10-K 21 Feb 2018 2017 FY
Q4 2014 $33,075,000 +$15,736,000 +91% 31 Dec 2014 10-K 09 Mar 2017 2016 FY
Q4 2013 $17,339,000 31 Dec 2013 10-K 11 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.